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Priapism, a rare but well-known adverse reaction of ﬁrst and second generation anti-psychotics, has
been hypothesized to be associated with blockade of alpha 1 receptors. However, genetic abnormalities
or heritability of affected cytochrome P450 alleles has not been ruled out as a causal mechanism. A case is
presented with three episodes of priapism within 17 days while taking standard FDA (Food and Drug
Administration) approved doses of quetiapine. Cytochrome P450 3A4 genotype testing was performed
and resulted with normal enzymatic activity. This case further eliminates enzymatic metabolism as a
possible cause of priapism, thus strengthening the alpha one receptor blockade hypothesis.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Case report
A divorced 48 year old Caucasian male presented to the emer-
gency department with a painful erection of nine hours duration
which woke him from sleep. He denied recent sexual activity or
arousal, use of phosphodiesterase inhibitors, sickle cell trait or
anemia, malignancy history, perineal trauma, or illicit drug use
whichwas conﬁrmed bynegative toxicology screening. He admitted
use of smokeless tobacco. Medical and psychiatric history included
hypertension, hypercholesterolemia, and schizoaffective disorder.
He was maintained on quetiapine 800 mg nightly for the past
10 years with brief periods of non-compliance and medication
changes. The most recent period of non-compliance was eight
months prior to presentation at which time he was admitted to an
inpatient psychiatric unit. Since discharge, he reported full compli-
ance with quetiapine 800 mg nightly, clonazepam 1mg three times
daily, atenolol 100 mg daily, hydrochlorothiazide 12.5 mg daily, and
pravastatin 40 mg nightly. Over-the-counter medications taken
include aspirin 81 mg daily and aspirin-caffeine powder packets for
occasional headaches. Compliance was conﬁrmed by pharmacy re-
cords and pill count. Physical examination revealed a fully erect
penis, circumcised phallus, and moderate tenderness throughout.
No erythema or indurationwas present, and bilateral testicles were
soft. The remaining genitourinary examination was unremarkable.þ1 601 984 5885.
nc. This is an open access article uHe appeared fully awake and alert. No signs of quetiapine overdose
including somnolence, tachycardia, respiratory depression, or hy-
potension were present. Laboratory data conﬁrmed normal com-
plete blood counts, electrolytes, and hepatic function. Urine gas
chromatography-mass spectroscopy (GCMS) was positive for nico-
tine, cotinine, lidocaine, and quetiapine metabolite. Given cyto-
chrome P450 3A4 is primarily responsible for quetiapine’s
metabolism, genotype testing was obtained. The cytochrome P450
study was done to rule out any enzymatic or genetic abnormality
interfering with metabolism of the above medications.1,2 Urology
was consulted and aspirated 15 cc of dark, red blood from the
bilateral corpora after local anesthesiawith 1% lidocaine. The patient
was given 1000 mcg of phenylephrine and 750 mg of levoﬂoxacin
orally. Aspiration of the corporal bodies resulted in gradual detu-
mescence and relief of the patient’s pain. After a three hour obser-
vation, he was medically cleared for discharge from the emergency
room. As this was the patient’s third episode of priapism within
17 days, psychiatry was consulted for recommendations as his pri-
apismwas speculated to be related to his psychotropic medications.
The previous two episodes had similar presentations to the one
described and resolved with improvement in pain after the proce-
dure by urology. Further history revealed two episodes of priapism
within one month approximately one year ago while taking chlor-
promazine. The patient was unaware of other medications taken in
addition to chlorpromazine. Following these occurrences, his pri-
marypsychiatrist promptly stopped chlorpromazine, and symptoms
did not recur until 17 days ago. During these episodes, the patient
denied recent sexual activity or arousal, use of phosphodiesterasender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Pharmacokinetic metabolism proﬁles
Medication CYP substrate Inducer of CYP Inhibitor of CYP
Aspirin 2C9 (minor) 2C19 (weak) None
Atenolol None None None
Chlorpromazine 1A2 (minor)
2D6 (major)
None 2D6 (moderate)
Clonazepam 3A4 (major) None None
Hydrochlorothiazide None None None
Pravastatin 3A4 (minor) None None
Quetiapine 3A4 (major)
2D6 (minor)
None None
J.C. Jackson, C.L. Torrence / Urology Case Reports 3 (2015) 1e22inhibitors, perineal trauma, or illicit druguse. Taking this history into
consideration, psychiatric consultation recommended not
exceeding the recommended daily dose of quetiapine, reducing
clonazepam1mg to twice daily, and following up promptlywith his
primary psychiatrist within 1 week for directions on discontinuing
quetiapine and cross-titrating to another anti-psychoticmedication.
Hewas instructed to return to the emergency department if another
episode occurred.
Comments
We report this case linking quetiapine, a second generation anti-
psychotic medication to priapism as there is limited data on anti-
psychotics and their link with priapism in the literature. Previous
cases involved a single ingestion or overdose of quetiapine outside
the therapeutic range or stable daily dosage within the therapeutic
range lacking further laboratory data or genetic testing linking
hepatic functioning or other medication interactions to the possi-
bility of causing priapism.3e5 In contrast to other cases, cytochrome
P450 3A4 genetic testing was performed as our patient clearly has a
propensity for priapism with use of daily dosed anti-psychotics
including his prior history one year ago.1,2 Furthermore, the pa-
tient denied taking more than the recommended daily dose of
quetiapine and the absence of other side effects that have beenpreviously linked to quetiapine overdose including somnolence,
tachycardia, respiratory depression, and hypotension.3 Any use of
illicit substances or other medications were ruled out by GCMS. As
quetiapine and clonazepam are signiﬁcant cytochrome P450 3A4
substrates, cytochrome genetic testing allowed a closer examina-
tion of the patient’s enzymatic functioning.1We hypothesized there
were likely malfunctioning hepatic cytochrome enzymes with a
major role in the medications’ metabolism either inherited or ac-
quired (Table 1). Upon review of his cytochrome lab results, the
patient had CYP 3A4 CC genotype, which predicts normal enzyme
activity. Direct polymorphism analysis of the CYP 3A4 allele was
performed by a polymerase chain reaction (PCR) based on 50-
nuclease assay using ﬂuorescently labeled detection probes, which
does not detect all CYP 3A4 genetic variants. As a result of CYP
testing, enzymatic and metabolizing abnormalities are less likely
the mechanism of the patient’s frequent emergency department
visits. These results do not exclude hepatic enzyme genetic abnor-
malities or confounding medication interactions as the cause, only
less likely in this patient. This suggests quetiapine’s alpha 1
adrenergic antagonist properties are the most likely cause of this
patient’s priapism.5Conﬂict of interest
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